/
DCF Valuation
Base-case fair value
$7.61
Intrinsic $10.15 · 25% MOS
Current price: $20.25
Base-case summary
Our base-case DCF for Castle Biosciences Inc (CSTL) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $5M in trailing free cash flow, this produces an intrinsic value of $10.15 per share. A 25% safety margin gives a fair value of $7.61, suggesting the stock is currently 62% overvalued against the $20.25 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$5M
Cash & equivalents
$262M
Total debt
$37M
Shares outstanding
30M